{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"197"}]}],"title":"Never-positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"131"}]}],"title":"Ever-positve"}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"ADA against avelumab in serum samples was determined and reported separately for ADA never-positive and ADA ever-positive participants. Participants were considered ADA ever-positive if they had at least one positive (ADA titer greater than or equal to 60 with assay cut point of 1.12) ADA result at any time point during 36 months and were otherwise considered negative. Data for this outcome measure was not planned to be collected and analyzed for reporting arm \"Chemotherapy followed by Observation\", since, avelumab was not administered in this arm.","groups":[{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W on Days 1, 15 and 29 of each 42 day cycle.","id":"OG000","title":"Immunogenicity: Chemotherapy Followed by Avelumab"},{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W along with avelumab Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W (on Days 1, 15 and 29 of each 42 day cycle).","id":"OG001","title":"Immunogenicity: Chemotherapy + Avelumab Followed by Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set included all participants who had received at least one dose of study drug and who had at least one ADA sample collected for avelumab in the avelumab containing arms. Here \"Overall number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 36 months","title":"Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status","type":"SECONDARY","unitOfMeasure":"Participants"}